Literature DB >> 10747133

New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

L Heifets1, T Sanchez.   

Abstract

A new agar medium to perform pyrazinamide (PZA) susceptibility testing with Mycobacterium tuberculosis has been developed. This medium has an acidic pH of 6.0 instead of the usual for agar media, pH 6.8, to provide optimal conditions for PZA activity, and it also differs from conventional Middlebrook 7H10/7H11 agar in that animal serum (fetal or calf bovine or fetal equine serum) is used instead of oleic acid-albumin-dextrose-catalase to support good growth of M. tuberculosis at the low pH of 6.0. A critical concentration of 900 or 1,200 microg of PZA/ml in this medium made it possible to differentiate between PZA-susceptible and PZA-resistant clinical isolates. This agar medium has the following advantages compared to a liquid medium: it allows determination of the actual proportion of PZA-resistant bacteria in the isolate and it is simple and inexpensive. In addition, it has the potential of being used for a direct susceptibility test with PZA, but this approach will require further confirmation. Further studies to develop critical concentrations of other drugs for this low-pH medium, as well as to investigate the possibility of cultivation in regular (non-CO(2)) incubators, are in progress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747133      PMCID: PMC86474     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

Review 1.  Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century.

Authors:  L B Heifets; G A Cangelosi
Journal:  Int J Tuberc Lung Dis       Date:  1999-07       Impact factor: 2.373

2.  Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar.

Authors:  K D Stottmeier; R E Beam; G P Kubica
Journal:  Am Rev Respir Dis       Date:  1967-11

3.  The resurgence of tuberculosis: is your laboratory ready?

Authors:  F C Tenover; J T Crawford; R E Huebner; L J Geiter; C R Horsburgh; R C Good
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

4.  Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing.

Authors:  D Hewlett; D L Horn; C Alfalla
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

5.  Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity.

Authors:  W R Butler; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

6.  Growth inhibition of Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC pyrazinamide susceptibility test.

Authors:  M A Miller; L Thibert; F Desjardins; S H Siddiqi; A Dascal
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

7.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.

Authors:  A Scorpio; P Lindholm-Levy; L Heifets; R Gilman; S Siddiqi; M Cynamon; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

8.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.

Authors:  A Scorpio; Y Zhang
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

9.  Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  W R Butler; J O Kilburn
Journal:  J Clin Microbiol       Date:  1982-12       Impact factor: 5.948

10.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

  10 in total
  14 in total

1.  Comparison of the ESP and BACTEC systems for testing susceptibilities of Mycobacterium tuberculosis complex isolates to pyrazinamide.

Authors:  Vincent J LaBombardi
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

3.  Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Authors:  J Werngren; E Sturegård; P Juréen; K Ängeby; S Hoffner; T Schön
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

4.  Requirement of the mymA operon for appropriate cell wall ultrastructure and persistence of Mycobacterium tuberculosis in the spleens of guinea pigs.

Authors:  Amit Singh; Radhika Gupta; R A Vishwakarma; P R Narayanan; C N Paramasivan; V D Ramanathan; Anil K Tyagi
Journal:  J Bacteriol       Date:  2005-06       Impact factor: 3.490

5.  Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis.

Authors:  Takemasa Takii; Sonomi Hamasaki; Kazue Hirano; Chiyoji Abe; Kikuo Onozaki
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Evaluation of Etest for susceptibility testing of Mycobacterium tuberculosis.

Authors:  M L Joloba; S Bajaksouzian; M R Jacobs
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

7.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

8.  Multicenter evaluation of a nonweekend reading schedule for radiometric pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  B Madison; W Gross; I George; A Sloutsky; G Washabaugh; B Robinson-Dunn; H Lipman; B Metchock; G Mazurek; J Ridderhof
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

9.  Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method.

Authors:  Man Zhou; Xuelei Geng; Jun Chen; Xude Wang; Dianbing Wang; Jiaoyu Deng; Zhiping Zhang; Weihua Wang; Xian-En Zhang; Hongping Wei
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

10.  The pyrazinamide susceptibility breakpoint above which combination therapy fails.

Authors:  Tawanda Gumbo; Emmanuel Chigutsa; Jotam Pasipanodya; Marianne Visser; Paul D van Helden; Frederick A Sirgel; Helen McIlleron
Journal:  J Antimicrob Chemother       Date:  2014-05-12       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.